Articles

“The study does not prove that erectile dysfunction drugs reduce the risk of Alzheimer’s disease,” the American Academy of Neurology said. “It only shows an association.”

Shares of Affirm were down about 6% in after-hours trading after soaring 10% during the regular session.

Pinterest Inc.’s stock initially plummeted 23% before rallying in extended trading Thursday after it reported a revenue miss.

What was novel four decades ago suddenly looks relevant again for the reeling U.S. commercial-real-estate industry.

Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.

Corn and soybean futures are falling, with disappointing U.S. mandates for plant-based renewable fuels contributing to weakness.

Inflation revisions don’t generally make waves. But they did last year and it’s for this reason that investors are preparing for what Friday’s updated data might show.

Stock is trading at $28 compared with Eli Lilly’s $739 price tag. That could change if a trial of a pill version of its GLP-1 drug proves effective.

Value investing is dead because passive investing has broken market structures, says hedge-fund legend David Einhorn.

Chili’s recently changed its menu design to try to prevent customers from ordering the starter as a main dish.

The economy is still booming by many measures — such as gross domestic product, job creation and unemployment — but Americans still aren’t all that happy.

While the cannabis business remains volatile, more educational programs are being launched as state-legal marijuana programs gear up.